Supplementary Figure 1 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Pathways targeted by the Dana-Farber Targeted Therapy Collection and clinical development status</p

Supplementary figure legends from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Legends to the supplementary figures</p

Supplementary Figure 2 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Comparison of compound libraries reported in ROS1 kinase screens</p

Supplementary Figure 4 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Chemical structures of lead compounds</p

Supplementary Tables 1 and 2 from FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLCs

PDF - 88KB, Supplementary Table 1. Relationships between FBXW7 expression and clinicopathological factors in 103 patients with NSCLC. Supplementary Table 2. Univariate and multivariate analysis of clinicopathological factors affecting the overall survival rate of patients with NSCLC following surgery.</p

Supplementary Figure 3 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Inhibition of Ba/F3 CD74-ROS1 proliferation</p

Supplementary file 1 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Contents of the Dana-Farber Targeted Therapy Library and raw data</p

Supplementary Figure 5-7 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Inhibition of ROS1 signaling in Ba/F3 and UMG-118 cells and the RNPC3-ROS1 fusion</p

Supplementary Figure 2 from FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLCs

PDF - 98KB, Supplementary Figure 2. FBXW7 expression in cell lines treated with MS-275.</p

Supplementary Figure Legend from FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLCs

PDF - 52KB, Legends for Supplementary Figures 1 and 2.</p